Page 14 - Lupin

Lupin revising product portfolio in US to overcome price erosion impact

Homegrown pharmaceutical firm Lupin Ltd is rationalising its product portfolio in the US, transitioning from simple oral solid medicines to more complex generics to overcome the impact of price erosion witnessed in the market, according to the company's CEO Vinita Gupta. With its planned product pipeline for complex generic medicines in the next two years, she said in the years to come the company hopes to have up to 40 per cent of its revenue coming from such medicines in the US market. "...Oral solids (are) still the bread and butter (for the company), but the kind of price erosion one has witnessed on the oral solid side, we decided that it made sense to rationalise the portfolio that does not make sense," she told analysts. Gupta further said, "Whether it's negative margin or low margin, it makes sense to really take the overhead out of our P&L (profit and loss) to improve profitability. We are taking those steps." She was responding to a query on Lupin's strategy to counter ..

Lupin reports Q1 net loss at Rs 89 cr on lower US sales; revenue falls 12%

'Our numbers are muted this quarter, but we expect a strong bounce back from Q2 onwards,' says Lupin MD

Stocks to Watch: ONGC, Reliance, Zomato, Adani Wilmar, IndiGo,Vodafone Idea

Stocks to Watch today: Uber has decided to put its entire 7.8 per cent stake in Zomato on the block, according to sources.

Sensex sheds 498 pts, Nifty below 16,500; Infy slips 3.5%, Axis Bank 3%

CLOSING BELL: Equity markets settled near the low point of the day as investors chose to stay on the sidelines ahead of the US Federal Reserve's monetary policy outcome on Wednesday

Stocks to watch: Asian Paints, Bajaj Auto, Tata Steel, Axis Bank, Lupin

Stocks to watch today: Asian Paints, Bajaj Auto will report their June quarter results (Q1FY23) on Tuesday, July 26; Lupin received approval from USFDA to market medication for high blood pressure.

Lupin gets USFDA approval for generic blood pressure lowering drug

Drug firm Lupin on Monday said it has received an approval from the US Health regulator to market generic medication to treat high blood pressure.

Torrent Pharma expected to enter diagnostics space in next 2-3 months

A company called Torrent Diagnostics Private Ltd was incorporated in February this year and has a Torrent Pharmaceuticals executive director as one of its directors

Stocks to Watch: Banks, Lupin, YES Bank, CG Electricals, Ujjivan SFB, Sugar

Stocks to Watch Today: Sugar industry has requested the government that the additional 1 MT export order be given the mills, and not trader or exporters.

Lupin receives tentative approval from USFDA to market Ivacaftor tablets

The product is the generic equivalent of Vertex Pharmaceuticals' Kalydeco tablets, Lupin said in a statement

Titan, Lupin, Indian Hotels: How to trade Rakesh Jhunjhunwala-owned stocks

Titan and Lupin seem poised for solid gains among Rakesh Jhunjhunwala's portfolio, while shares of Lupin, Star Health and Jubilant Pharmova can be avoided for now.

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

Investors poorer by Rs 7 trn as Sensex crashes 1,416pts; Nifty holds 15,800

CLOSING BELL: The Nifty IT index plunged 6 per cent on the NSE today after global brokerage JPMorgan downgraded the sector to "underweight".

Lupin slips 9%, hits 2-year low on disappointing March quarter results

Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than anticipated traction this quarter.

Stocks to Watch: ITC, Lupin, Ruchi Soya, Manappuram Finance, JSW, Biocon

Stocks to Watch: The US markets suffered the biggest one-day sell-off in almost two years -Investors worry about inflation and its impact on earnings and prospects for monetary policy tightening

Lupin logs net loss of Rs 512 cr in Q4 on rising costs, impairment expense

Quarter was challenging due to 'headwinds in the US on account of price erosion', says company.

Rejuvenating Cipla: After global expansion, acquisitions on cards

Having consolidated its presence across geographies, the pharma major is looking at acquisitions

Lupin receives USFDA approval for anti-depressant drug

It is the generic equivalent of Pristiq, extended-release tablets, 25 mg of PF PRISM C.V, it added

Lupin launches generic contraceptive drug Merzee capsules in US

Slayback had earlier launched this product in the US in February 2021

Lupin inks licensing pact with Alvion to market drugs in Southeast Asia

The Mumbai-based company said it is committed to providing affordable treatment options to healthcare providers and patients

Markets start FY23 with solid gains; Sensex jumps 708pts, Nifty tops 17,650

CLOSING BELL: Sectorally, the Nifty PSU Bank index jumped 4 per cent on the bourses with Union Bank, Bank of India, Canara Bank, and Bank of Maharashtra adding over 4 per cent each